eli lilly glp 1 drug Orforglipron: Lilly's New Oral GLP-1 Weight-loss Pill The Food and Drug Administration
Description
GLP-1 medications such as Ozempic and Wegovy have significantly reshaped the weight loss market by improving blood sugar regulation, insulin sensitivity, and appetite control
GLP-1, generally sh
Even more concerning
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and kidney benefits in the general population with type 2 diabetes mellitus (T2DM), evidence regarding their effects in diabetic KTRs is limited
To further note, in the field of weight-loss treatment, significant work is underway in parallel, on GIP agonist, amylin agonist, glucagon agonist, PYY agonist, either separately or in combination especially with GLP-1 agonist.
In 2025 we saw label expansions for semaglutide and tirzepatide, underscoring a trend toward whole-body health
